Daily Roundup

SEQ.ASX IFL.ASX HUM.ASX 1AD.ASX MEM.ASX

Sequoia Financial Group Requests Trading Halt, Pending Divestment Announcement

Sequoia Financial Group Ltd (ASX: SEQ) has requested an immediate trading halt on its shares, pending the release of an announcement regarding the divestment of a subsidiary. The trading halt will remain in place until the earlier of the announcement's release or the market open on March 23.

The company is not aware of any reason why the trading halt should not be granted. This suggests Sequoia is preparing to share material information with the market about a significant corporate transaction involving one of its business units.

Investors will be eager to learn more details about this potential divestment when Sequoia makes its announcement in the coming days. The trading pause is likely to generate speculation and interest as the market awaits further clarity from the financial services firm.

Insignia Financial Receives APRA Approval for Acquisition

In other news, Insignia Financial Ltd (ASX: IFL) has received approval from the Australian Prudential Regulation Authority (APRA) for the proposed acquisition of the company by Daintree Bidco Pty Ltd.

This APRA approval was a key regulatory condition for the Scheme of Arrangement, as previously announced in July 2025. The Insignia Financial Board continues to unanimously recommend that shareholders vote in favor of the scheme, in the absence of a superior proposal.

The Independent Expert has concluded that the Scheme is fair and reasonable and in the best interests of Insignia Financial shareholders. The acquisition remains subject to other conditions, including shareholder and court approval.

AdAlta Granted New AD-214 Patent in Canada

Turning to the healthcare sector, AdAlta Limited (ASX: 1AD) has announced that it has been granted a new composition of matter patent for its lead product AD-214 in Canada. This patent, valid until 2036, completes global patent protection for AD-214 in major commercial markets.

The new Canadian patent covers the i-body sequence used in AD-214, as well as related pharmaceutical compositions and therapeutic applications. With patents now secured in key regions like the US, EU, and Japan, AdAlta has solidified its intellectual property position for this first-in-class anti-fibrotic treatment.

Memphasys Maintains MENA Operations, Secures New Orders

Finally, Memphasys Limited (ASX: MEM) has confirmed that its commercial operations across the Middle East and North Africa (MENA) region remain unaffected by the ongoing regional instability.

Despite the geopolitical challenges, Memphasys has secured new orders from customers in the UAE and Iraq, demonstrating the continued regional demand for its Felix™ System used in assisted reproductive technology. The company is also progressing regulatory approvals to enter the key markets of Egypt and Turkey.

Memphasys' resilient business model, focused on direct clinic engagement and recurring cartridge revenue, has allowed it to navigate the regional uncertainty. The company remains confident in the continued rollout of its technology across the MENA region and broader international markets.